---
title: "Scalable Causal-Interpretable ML for Cancer Prescreening from Electronic Health Records"
id: "medrxiv-15-scalable-causal-interpretable-machine-learning-for-cancer-prescreening-using"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-scalable-causal-interpretable-machine-learning-for-cancer-prescreening-using"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.21.26363536v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Scalable Causal-Interpretable ML for Cancer Prescreening from Electronic Health Records
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-scalable-causal-interpretable-machine-learning-for-cancer-prescreening-using
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.21.26363536v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Electronic health records (EHRs) are valuable for disease risk prediction but many machine learning models learn opaque associations that are hard to inspect for clinical reasoning. - **Causal Bayesian networks (CBNs)** represent conditional dependencies, directional relations, and probabilistic evidence propagation in directed acyclic graphs, offering causal-interpretability. - Conventional CBN structure learning is unstable and computationally expensive on large-scale, high-dimensional EHR data. - The authors propose **UPEBNL**, a scalable framework that combines adaptive data slicing, quality-aware structure aggregation, and global directed acyclic graph (DAG) construction to learn stable dependency structures from large observational datasets. - UPEBNL was tested in high-dimensional, multi-million-sample simulations and on real-world EHR prescreening for **esophageal** and **colorectal cancer**. - In simulations, UPEBNL improved structural recovery accuracy by nearly 40% compared with conventional strategies and achieved up to a **221.28-fold speedup**. - For EHR-based cancer risk prediction, learned CBNs produced interpretable evidence paths and achieved validation **AUCs** of **0.8171** for esophageal cancer and **0.784** for colorectal cancer. - Calibration and decision curve analyses reported in the source supported model reliability and potential clinical utility. - The real-world EHR data used are not publicly available due to privacy and institutional governance; access may be possible via request and agreement with custodians. - Study received IRB approval (School of Public Health, Shandong University; approval number LL20240308). - Funders included the National Natural Science Foundation of China, China Postdoctoral Science Foundation, and the National Key Research and Development Program of China. - The authors declared no competing interests.
## Clinical Analysis & Structured Key Points
Scalable Causal-Interpretable Machine Learning for Cancer Prescreening Using Electronic Health Records | medRxiv Skip to main content Scalable Causal-Interpretable Machine Learning for Cancer Prescreening Using Electronic Health Records Shuaijie Zhang , Fuzhong Xue doi: https://doi.org/10.64898/2026.09.21.26363536 Shuaijie Zhang 1 Beijing Institute of Mathematical Sciences and Applications; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fuzhong Xue 2 Shandong University Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: xuefzh{at}sdu.edu.cn Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Electronic health records provide a source of real-world information for disease risk prediction, but many machine learning models learn implicit associations that are difficult to inspect or use for clinical reasoning. Causal Bayesian networks (CBNs) offer a form of causal-interpretable machine learning by representing conditional dependencies, putative directional relations, and probabilistic evidence propagation in a directed acyclic graph. However, conventional CBN structure learning becomes unstable and computationally expensive when applied to large-scale EHR data. To address this limitation, we propose UPEBNL, a scalable framework for causal-interpretable cancer prescreening based on parallel CBN learning. UPEBNL integrates adaptive data slicing, quality-aware structure aggregation, and global DAG construction to learn stable and interpretable dependency structures from large-scale observational data. We evaluated UPEBNL in high-dimensional and multi-million-sample simulations and applied it to EHR-based prescreening for esophageal and colorectal cancer. In simulations, UPEBNL improved structural recovery accuracy by nearly 40% and achieved up to a 221.28-fold speedup over conventional CBN learning strategies. For cancer risk prediction, the learned CBNs provided interpretable evidence paths and achieved validation AUCs of 0.8171 for esophageal cancer and 0.784 for colorectal cancer. Calibration and decision curve analyses further supported the reliability and clinical utility of the models. These findings suggest that scalable CBN learning can support interpretable cancer prescreening from large-scale EHR data. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Institutional Review Board of the School of Public Health, Shandong University, China (approval number: LL20240308). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The simulation datasets were generated according to the procedures described in the manuscript. The real-world electronic health record data are not publicly available because they contain sensitive health information and are subject to institutional data governance restrictions. Access to the data may be granted upon reasonable request to the corresponding author, subject to approval by the relevant data custodian and completion of applicable data-use and data-security agreements. Funder Information Declared National Natural Science Foundation of China , 82330108 China Postdoctoral Science Foundation , 2026M790787 National Key Research and Development Program of China , 2020YFC2003500 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Scalable Causal-Interpretable Machine Learning for Cancer Prescreening Using Electronic Health Records Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Scalable Causal-Interpretable Machine Learning for Cancer Prescreening Using Electronic Health Records Shuaijie Zhang , Fuzhong Xue medRxiv 2026.09.21.26363536; doi: https://doi.org/10.64898/2026.09.21.26363536 Share This Article: Copy Citation Tools Scalable Causal-Interpretable Machine Learning for Cancer Prescreening Using Electronic Health Records Shuaijie Zhang , Fuzhong Xue medRxiv 2026.09.21.26363536; doi: https://doi.org/10.64898/2026.09.21.26363536 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4835) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1634) Epidemiology (15982) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7070) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5070) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16313) Intensive Care and Critical Care Medicine (1177) Medical Education (673) Medical Ethics (155) Nephrology (727) Neurology (7308) Nursing (370) Nutrition (1087) Obstetrics and Gynecology (1245) Occupational and Environmental Health (1007) Oncology (3622) Ophthalmology (1058) Orthopedics (398) Otolaryngology (458) Pain Medicine (476) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5923) Public and Global Health (9778) Radiology and Imaging (2437) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (293)
## Related Clinical Research

- [BMI and Recurrence-Free Survival in Early-Onset Colorectal Cancer: A Cohort Analysis](https://medichelpline.com/clinical-feed/medrxiv-3-weighing-the-odds-body-mass-index-and-recurrence-free-survival-in-early-onset.md)
- [Structured aerobic exercise linked to lower cancer recurrence and improved survival](https://medichelpline.com/clinical-feed/medical-news-today-0-aerobic-exercise-could-help-improve-outlook-after-cancer-treatment.md)
- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [Human-like sialome (CMAH loss) links hyperglycemia to accelerated colorectal cancer progression](https://medichelpline.com/clinical-feed/biorxiv-0-human-like-sialome-remodeling-links-hyperglycemia-to-colorectal-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.